🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

NOX4 and Related Biomarkers in ADPKD

Recruitingn/aAges 15 Years - 40 YearsAllMayo Clinic
NCT04630613 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * ADPKD (based on Ravine et al. criteria) * Class 1 A-E according to imaging classification * Male and female subjects 15 - 40 years of age * Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI) * Ability to provide written, informed consent Exclusion Criteria: * Class 2 according to imaging classification * Concomitant systemic disease affecting the kidney * Diabetes mellitus * Predicted urine protein excretion in \>1 g/24 hrs * Use of antioxidants i.e. vitamins, Nrf2 activators * Abnormal urinalysis
💊

What it tests

  • Not listed
📍

Where

1 site
Mayo Clinic
Rochester, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy